Item 8.01 Other Events.

On March 31, 2020, bluebird bio, Inc. ("bluebird") and Bristol Myers Squibb Company issued a press release announcing the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the product candidate idecabtagene vicleucel (ide-cel; bb2121) for the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.

The full text of bluebird's press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits
    Exhibit
      No.                                              Description
     99.1               Press release issued by bluebird bio, Inc. on March     3    1    , 2020  .
      104             Cover Page Interactive Data File (embedded within the Inline XBRL document)





--------------------------------------------------------------------------------

© Edgar Online, source Glimpses